GT Biopharma, Inc.
GTBP
$5.98
$0.7414.13%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 3.46M | 2.44M | 4.22M | 2.75M | 1.15M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.51M | 2.85M | 5.60M | 3.38M | 1.51M |
| Operating Income | -4.51M | -2.85M | -5.60M | -3.38M | -1.51M |
| Income Before Tax | -4.52M | -2.83M | -23.03M | -3.11M | -30.17M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -4.52M | -2.83M | -23.03M | -3.11M | -30.17M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.52M | -2.83M | -23.03M | -3.11M | -30.17M |
| EBIT | -4.51M | -2.85M | -5.60M | -3.38M | -1.51M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -2.96 | -2.78 | -55.67 | -20.67 | -272.88 |
| Normalized Basic EPS | -1.82 | -1.46 | -27.73 | -12.35 | -170.07 |
| EPS Diluted | -2.96 | -2.78 | -55.67 | -20.67 | -272.88 |
| Normalized Diluted EPS | -1.82 | -1.46 | -27.73 | -12.35 | -170.07 |
| Average Basic Shares Outstanding | 1.55M | 1.21M | 519.10K | 157.60K | 110.90K |
| Average Diluted Shares Outstanding | 1.55M | 1.21M | 519.10K | 157.60K | 110.90K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -0.63% | -2.73% | -- |